Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunity

Jessica J. O'Konek, Petr Illarionov, Deborah Stewart Khursigara, Elena Ambrosino, Liat Izhak, Bernard F. Castillo, Ravinder Raju, Maryam Khalili, Hee Yong Kim, Amy R. Howell, Gurdyal S. Besra, Steven A. Porcelli, Jay A. Berzofsky, Masaki Terabe

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Type 1 or invariant NKT (iNKT) cell agonists, epitomized by α-galactosylceramide, protect against cancer largely by IFN-γ-dependent mechanisms. Here we describe what we believe to be a novel IFN-γ-independent mechanism induced by β-mannosylceramide, which also defines a potentially new class of iNKT cell agonist, with an unusual β-linked sugar. Like α-galactosylceramide, β-mannosylceramide directly activates iNKT cells from both mice and humans. In contrast to α-galactosylceramide, protection by β-mannosylceramide was completely dependent on NOS and TNF-α, neither of which was required to achieve protection with α-galactosylceramide. Moreover, at doses too low for either alone to protect, β-mannosylceramide synergized with α-galactosylceramide to protect mice against tumors. These results suggest that treatment with β-mannosylceramide provides a distinct mechanism of tumor protection that may allow efficacy where other agonists have failed. Furthermore, the ability of β-mannosylceramide to synergize with α-galactosylceramide suggests treatment with this class of iNKT agonist may provide protection against tumors in humans.

Original languageEnglish (US)
Pages (from-to)683-694
Number of pages12
JournalJournal of Clinical Investigation
Volume121
Issue number2
DOIs
StatePublished - Feb 1 2011

Fingerprint

Galactosylceramides
Natural Killer T-Cells
Immunity
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

O'Konek, J. J., Illarionov, P., Khursigara, D. S., Ambrosino, E., Izhak, L., Castillo, B. F., ... Terabe, M. (2011). Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunity. Journal of Clinical Investigation, 121(2), 683-694. https://doi.org/10.1172/JCI42314

Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunity. / O'Konek, Jessica J.; Illarionov, Petr; Khursigara, Deborah Stewart; Ambrosino, Elena; Izhak, Liat; Castillo, Bernard F.; Raju, Ravinder; Khalili, Maryam; Kim, Hee Yong; Howell, Amy R.; Besra, Gurdyal S.; Porcelli, Steven A.; Berzofsky, Jay A.; Terabe, Masaki.

In: Journal of Clinical Investigation, Vol. 121, No. 2, 01.02.2011, p. 683-694.

Research output: Contribution to journalArticle

O'Konek, JJ, Illarionov, P, Khursigara, DS, Ambrosino, E, Izhak, L, Castillo, BF, Raju, R, Khalili, M, Kim, HY, Howell, AR, Besra, GS, Porcelli, SA, Berzofsky, JA & Terabe, M 2011, 'Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunity', Journal of Clinical Investigation, vol. 121, no. 2, pp. 683-694. https://doi.org/10.1172/JCI42314
O'Konek JJ, Illarionov P, Khursigara DS, Ambrosino E, Izhak L, Castillo BF et al. Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunity. Journal of Clinical Investigation. 2011 Feb 1;121(2):683-694. https://doi.org/10.1172/JCI42314
O'Konek, Jessica J. ; Illarionov, Petr ; Khursigara, Deborah Stewart ; Ambrosino, Elena ; Izhak, Liat ; Castillo, Bernard F. ; Raju, Ravinder ; Khalili, Maryam ; Kim, Hee Yong ; Howell, Amy R. ; Besra, Gurdyal S. ; Porcelli, Steven A. ; Berzofsky, Jay A. ; Terabe, Masaki. / Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunity. In: Journal of Clinical Investigation. 2011 ; Vol. 121, No. 2. pp. 683-694.
@article{218a9225a4d74bc78b0cc1666eec4408,
title = "Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunity",
abstract = "Type 1 or invariant NKT (iNKT) cell agonists, epitomized by α-galactosylceramide, protect against cancer largely by IFN-γ-dependent mechanisms. Here we describe what we believe to be a novel IFN-γ-independent mechanism induced by β-mannosylceramide, which also defines a potentially new class of iNKT cell agonist, with an unusual β-linked sugar. Like α-galactosylceramide, β-mannosylceramide directly activates iNKT cells from both mice and humans. In contrast to α-galactosylceramide, protection by β-mannosylceramide was completely dependent on NOS and TNF-α, neither of which was required to achieve protection with α-galactosylceramide. Moreover, at doses too low for either alone to protect, β-mannosylceramide synergized with α-galactosylceramide to protect mice against tumors. These results suggest that treatment with β-mannosylceramide provides a distinct mechanism of tumor protection that may allow efficacy where other agonists have failed. Furthermore, the ability of β-mannosylceramide to synergize with α-galactosylceramide suggests treatment with this class of iNKT agonist may provide protection against tumors in humans.",
author = "O'Konek, {Jessica J.} and Petr Illarionov and Khursigara, {Deborah Stewart} and Elena Ambrosino and Liat Izhak and Castillo, {Bernard F.} and Ravinder Raju and Maryam Khalili and Kim, {Hee Yong} and Howell, {Amy R.} and Besra, {Gurdyal S.} and Porcelli, {Steven A.} and Berzofsky, {Jay A.} and Masaki Terabe",
year = "2011",
month = "2",
day = "1",
doi = "10.1172/JCI42314",
language = "English (US)",
volume = "121",
pages = "683--694",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "2",

}

TY - JOUR

T1 - Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunity

AU - O'Konek, Jessica J.

AU - Illarionov, Petr

AU - Khursigara, Deborah Stewart

AU - Ambrosino, Elena

AU - Izhak, Liat

AU - Castillo, Bernard F.

AU - Raju, Ravinder

AU - Khalili, Maryam

AU - Kim, Hee Yong

AU - Howell, Amy R.

AU - Besra, Gurdyal S.

AU - Porcelli, Steven A.

AU - Berzofsky, Jay A.

AU - Terabe, Masaki

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Type 1 or invariant NKT (iNKT) cell agonists, epitomized by α-galactosylceramide, protect against cancer largely by IFN-γ-dependent mechanisms. Here we describe what we believe to be a novel IFN-γ-independent mechanism induced by β-mannosylceramide, which also defines a potentially new class of iNKT cell agonist, with an unusual β-linked sugar. Like α-galactosylceramide, β-mannosylceramide directly activates iNKT cells from both mice and humans. In contrast to α-galactosylceramide, protection by β-mannosylceramide was completely dependent on NOS and TNF-α, neither of which was required to achieve protection with α-galactosylceramide. Moreover, at doses too low for either alone to protect, β-mannosylceramide synergized with α-galactosylceramide to protect mice against tumors. These results suggest that treatment with β-mannosylceramide provides a distinct mechanism of tumor protection that may allow efficacy where other agonists have failed. Furthermore, the ability of β-mannosylceramide to synergize with α-galactosylceramide suggests treatment with this class of iNKT agonist may provide protection against tumors in humans.

AB - Type 1 or invariant NKT (iNKT) cell agonists, epitomized by α-galactosylceramide, protect against cancer largely by IFN-γ-dependent mechanisms. Here we describe what we believe to be a novel IFN-γ-independent mechanism induced by β-mannosylceramide, which also defines a potentially new class of iNKT cell agonist, with an unusual β-linked sugar. Like α-galactosylceramide, β-mannosylceramide directly activates iNKT cells from both mice and humans. In contrast to α-galactosylceramide, protection by β-mannosylceramide was completely dependent on NOS and TNF-α, neither of which was required to achieve protection with α-galactosylceramide. Moreover, at doses too low for either alone to protect, β-mannosylceramide synergized with α-galactosylceramide to protect mice against tumors. These results suggest that treatment with β-mannosylceramide provides a distinct mechanism of tumor protection that may allow efficacy where other agonists have failed. Furthermore, the ability of β-mannosylceramide to synergize with α-galactosylceramide suggests treatment with this class of iNKT agonist may provide protection against tumors in humans.

UR - http://www.scopus.com/inward/record.url?scp=79551572107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551572107&partnerID=8YFLogxK

U2 - 10.1172/JCI42314

DO - 10.1172/JCI42314

M3 - Article

C2 - 21245578

AN - SCOPUS:79551572107

VL - 121

SP - 683

EP - 694

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 2

ER -